biotech · Relapsed/Refractory Large B Cell Lymphoma · Relapsed/Refractory Multiple Myeloma · ALLO
Allogene Therapeutics
Allogene Therapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2017
- Employees
- 208
- Programs
- 8
- Drugs
- 2
- Patents
- 16
Allogene Therapeutics projects
8 ClinicalTrials.gov programs sponsored by Allogene Therapeutics.
Allogene Therapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ALLO-501A
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
1 trial -
ALLO-605
Allogene Therapeutics
Relapsed/Refractory Multiple Myeloma
1 trial -
ALLO-647
Allogene Therapeutics
Relapsed/Refractory Large B Cell Lymphoma
1 trial -
cemacabtagene ansegedleucel
Allogene Therapeutics
Large B-cell Lymphoma
1 trial -
ALLO-316
Allogene Therapeutics
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
1 trial -
ALLO-329
Allogene Therapeutics
Systemic Lupus Erythematosus (With and Without Nephritis)
1 trial -
ALLO-501
Allogene Therapeutics
Relapsed/Refractory Large B Cell Lymphoma
1 trial -
ALLO-715
Allogene Therapeutics
Relapsed/Refractory Multiple Myeloma
1 trial
Frequently asked questions
How many clinical projects does Allogene Therapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.